TB-500 (Thymosin Beta-4): 2026 Tissue Repair Guide

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 8-6-1 to add TB-500 to the §503A compounding bulk drug substances list. This is an advisory recommendation to FDA, not a final rule, and does not by itself authorize compounding pharmacies to prepare TB-500 for patients today. FDA still decides through notice-and-comment rulemaking, and the timeline is months to more than a year. For the full context, see our PCAC vote explainer.
TB-500 , commonly used as shorthand for Thymosin Beta-4 (Tβ4) , is one of the most-discussed tissue-repair peptides of 2026. After the February 27, 2026 HHS reclassification announcement, TB-500 is once again compoundable by prescription at 503A pharmacies in the United States. This guide covers everything a newly-prescribed patient or experienced biohacker needs: how TB-500 works, the loading-vs-maintenance dosing paradigm that defines its protocols, reconstitution math, the standard 2.5 mg twice-weekly clinical dose vs the more aggressive community ranges, side effects, the Wolverine Stack pairing with BPC-157, costs, and the regulatory outlook heading into the July 2026 FDA review. The protocols below distinguish between clinically validated dosing and community-reported ranges so you can match guidance to your situation.
Table of Contents
- What is TB-500?
- How TB-500 Works
- 2026 Regulatory Status
- Standard Dosing Protocols
- Loading vs Maintenance
- Frequency and Cycle Lengths
- Reconstitution Math
- Half-Life
- Side Effects and Management
- Drug interactions
- Cycle Lengths
- Lab Monitoring
- Storage & Travel
- Common Stacks and Combinations
- Cost Considerations
- Frequently Asked Questions
What is TB-500?
TB-500 is commonly used as a synonym for Thymosin Beta-4 (Tβ4), but it is technically a synthetic fragment corresponding to the active region of Tβ4, specifically the 17LKKTETQ23 actin-binding domain. Many community products historically supplied this fragment; full-length Tβ4 is now also dispensed by compounding pharmacies. For most clinical purposes the names are used interchangeably.
Full-length Thymosin Beta-4 is a 43-amino-acid peptide and the most abundant member of the β-thymosin family in mammalian tissue. It is especially prominent in platelets and wound-healing cells. Among healing peptides, TB-500 has one of the strongest human safety records, owing to RegeneRx Biopharmaceuticals’ development of RGN-259 , a Tβ4-based ophthalmic drop for dry eye that advanced through Phase 3 clinical trials in the 2010s.
How TB-500 Works
The primary mechanism of Thymosin Beta-4 is G-actin sequestration. Tβ4 binds free actin monomers inside the cell, regulating the rate at which actin filaments polymerize. Because actin polymerization drives cell migration, this mechanism allows Tβ4 to modulate the movement of:
- Endothelial cells (driving angiogenesis and vascular repair)
- Keratinocytes (driving skin and corneal wound closure)
- Cardiac progenitor cells (epicardial-derived progenitors recruited after injury, an active area of cardiac repair research)
This cell-migration mechanism is mechanistically complementary to BPC-157’s angiogenesis and NO-pathway effects, which is the rationale for the Wolverine Stack discussed below.
2026 Regulatory Status
Category 1 as of February 27, 2026. TB-500 / Thymosin Beta-4 was among the 14 of 19 peptides reclassified from FDA Category 2 back to Category 1 in the HHS announcement. Compounding pharmacies including Tailwind Nutrition, Empower Pharmacy, and Hallandale resumed dispensing in March 2026, and telehealth peptide clinics have it back in their formularies. The first-batch FDA safety review concludes July 2026.
RegeneRx’s published Phase 3 dataset for RGN-259 means TB-500/Tβ4 enters this review with a stronger human-exposure record than most peptides in the cohort.
Standard Dosing Protocols
Compounding pharmacy / clinical (post-Feb 2026):
- Typical script: 2 mg or 2.5 mg subcutaneous, twice weekly, for 4–6 weeks
- Some prescribers use 5 mg twice weekly for the first 2 weeks as a loading phase, then drop to 2.5 mg twice weekly
- Generally dispensed in 5 mg vials (one vial = ~1 week at 2.5 mg twice weekly)
Community-reported (r/Peptides, ExploringPeptides.com, peptidedeck.com):
- Loading phase: 5–10 mg/week, split into 2 doses (e.g., 2.5 mg or 5 mg twice weekly), for 4–6 weeks
- Maintenance: 2–2.5 mg once or twice weekly
- Aggressive injury (off-label, often discussed in bodybuilding contexts): up to 20 mg/week during loading
| Goal | Typical Weekly Dose | Frequency | Duration |
|---|---|---|---|
| Acute soft-tissue injury (clinical) | 4–5 mg | 2 mg or 2.5 mg 2x/week | 4–6 weeks |
| Acute injury (community loading) | 5–10 mg | 2.5–5 mg 2x/week | 4–6 weeks |
| Chronic tendinopathy | 4–5 mg | 2.5 mg 2x/week | 6–8 weeks |
| Maintenance / recovery | 2–2.5 mg | 1x/week | Cycled |
| Aggressive bodybuilder protocol | 10–20 mg | 5–10 mg 2x/week | 4 weeks (off-label) |
Loading vs Maintenance
The loading-then-maintenance paradigm is one of the most consistently described features of TB-500 protocols across both community and clinical sources. The rationale: Tβ4’s slow tissue equilibration and long functional half-life mean tissue saturation takes weeks. Once tissue is saturated, a lower dose maintains that level.
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Loading | 5–10 mg | 2x/week | 4–6 weeks |
| Maintenance | 2–2.5 mg | 1–2x/week | Indefinite or cycled |
Frequency and Cycle Lengths
- Twice weekly is the modal protocol across r/Peptides, ExploringPeptides.com, peptidedeck.com, and compounding pharmacy patient guides. Common pairing: Monday and Thursday.
- A minority approach favors daily lower-dose (e.g., 500 mcg/day) , proponents argue smoother tissue exposure; detractors note Tβ4’s long functional half-life makes daily dosing unnecessary.
- Once weekly is used for maintenance only, not for active injury.
- Standard cycle: 6–8 weeks on, 4 weeks off.
- Wolverine Stack cycle: 4–6 weeks on, paired with BPC-157.
- Long-term continuous use has not been studied in humans.
Reconstitution Math
TB-500 is supplied as a lyophilized powder. Reconstitute with bacteriostatic water (BAC water, sterile water with 0.9% benzyl alcohol). The two most common recipes:
| Vial | BAC Water Added | Concentration | For 2.5 mg, draw | For 5 mg, draw |
|---|---|---|---|---|
| 5 mg | 2.5 mL | 2 mg/mL | 1.25 mL | 2.5 mL (full vial) |
| 5 mg | 5 mL | 1 mg/mL | 2.5 mL | 5 mL (full vial) |
| 10 mg | 5 mL | 2 mg/mL | 1.25 mL | 2.5 mL |
The 5 mg + 2.5 mL recipe (2 mg/mL) is the most-referenced ratio on peptidefox.com. The 5 mg + 5 mL recipe (1 mg/mL) gives easier insulin-syringe reading and has become more common in pharmacy patient guides since February 2026. Note that TB-500 doses are large enough that a U-100 insulin syringe (max 1 mL) may not draw a single dose at lower concentrations, many patients use a 3 mL syringe instead.
Half-Life
- Plasma half-life (full-length Tβ4): approximately 2 hours, based on PK data from the RGN-259 ophthalmic program and earlier IV studies.
- Functional half-life in tissue is much longer, likely days, given tissue binding to actin pools, which is why twice-weekly dosing works despite a short plasma half-life.
- TB-500 fragments may have shorter plasma half-life than full-length Tβ4.
Side Effects and Management
- Injection-site reactions , most common. Rotate sites and use a fresh needle each injection.
- Transient fatigue, lethargy, or “heavy” feeling 12–24 hours post-injection, frequently reported on r/Peptides, especially after loading-dose injections.
- Mild flu-like symptoms in the first week of loading.
- Headache , occasional.
- Theoretical concerns parallel BPC-157: pro-angiogenic, pro-migratory activity raises hypothetical concern about facilitating tumor progression in the presence of occult cancer. There is no human data either way. Discuss with your prescriber if you have a personal or family history of cancer.
Drug interactions
TB-500 has not been studied in any formal pharmacokinetic drug-drug interaction trial in humans. As a synthetic thymosin-beta-4 fragment given subcutaneously, it is expected to undergo peptidase clearance rather than meaningful CYP450 metabolism, so classic enzyme-mediated interactions appear unlikely on mechanistic grounds. Proposed effects on actin polymerization, angiogenesis, and tissue repair raise theoretical overlap with vasoactive and antiplatelet drugs. Always consult a prescriber before combining TB-500 with anticoagulants, antiplatelets, or other agents affecting bleeding risk.
Drug interactions to know
Published interaction data for TB-500 (Thymosin β-4) is limited. Always consult your prescribing physician or pharmacist before combining with prescription medications, supplements, or other substances. See our interactions lookup.
Cycle Lengths
Cycling summary: Community loading 4-6 weeks, 2x/wk; then weekly maintenance; then 4-week break.
The typical cycle pattern for TB-500 (Thymosin β-4) is 5 weeks on, 4 weeks off. Users often log time-off cycles alongside on-cycles to track receptor sensitivity, biomarker recovery, and any rebound effects. The off-cycle is not a period of "washout only" but an active reset window worth using for a lab draw.
Lab Monitoring
TB-500 (Thymosin β-4) is a research-tier healing peptide with no established peripheral efficacy biomarker. Lab monitoring should be prudent general-health surveillance rather than efficacy tracking. The panels below cover organ systems most relevant during peptide research use.
Baseline (before starting): CBC with differential, comprehensive metabolic panel (CMP) covering LFTs and renal function, fasting lipid panel, hs-CRP for inflammatory baseline, fasting glucose, and HbA1c if metabolic risk factors are present. Age-appropriate cancer screening is prudent given rodent-only data on healing/angiogenic activity for most research peptides in this class.
During use: repeat CMP + CBC every 8-12 weeks. Repeat hs-CRP alongside if using for inflammatory conditions to track the inflammatory read against symptom response. Watch trends in ALT/AST (liver) and eGFR (renal) rather than single readings.
What to flag to a physician: injection-site erythema or nodule formation, unexplained weight changes, new joint or mass symptoms, any lab value trending outside reference range across two consecutive draws.
For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.
Storage & Travel
Storage
Lyophilized powder: Freezer -20°C (-4°F) long-term; protect from light.
Reconstituted: Refrigerate 2-8°C (36-46°F); use within 28 days in BAC water; do not freeze. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.
Travel
Domestic flights: pack reconstituted vials in an insulated cooler with reusable ice packs. The TSA 3-1-1 rule limits liquids to 100 mL per container in carry-on; a 3-5 mL peptide vial passes with room to spare. Keep pharmacy or vendor documentation visible for TSA questions. Lyophilized powder in original sealed vial does not require cooling for short trips.
International travel: TB-500 (Thymosin β-4) is a research peptide in most jurisdictions with varying import restrictions — check the destination country’s rules before travel. Carry a physician’s letter if the peptide was prescribed by a compounding-focused clinician.
Road trips: keep the cooler in the cabin, not the trunk, during summer. Hotel mini-fridges vary in temperature stability; an insulated bag inside the mini-fridge adds a buffer.
Emergency out-of-fridge: reconstituted TB-500 (Thymosin β-4) at room temperature under 24 hours is generally still viable per USP stability guidance. Longer excursions or temperatures above 30°C compromise potency; discard and reconstitute a fresh vial.
Common Stacks and Combinations
- Wolverine Stack (BPC-157 + TB-500) , the dominant healing combination. See our dedicated Wolverine Stack guide for the standard, aggressive, and conservative-clinical protocol variants. Also see the BPC-157 guide.
- TB-500 + GHK-Cu , wound and skin healing; see the GHK-Cu guide.
- TB-500 + Thymosin Alpha-1 , recovery + immune support, especially post-illness or post-surgical. See the Thymosin Alpha-1 guide.
- TB-500 + IGF-1 LR3 , bodybuilder injury recovery (off-label).
Cost Considerations
- Compounding pharmacy: $180–$320 for a 5 mg vial. TB-500 is more expensive than BPC-157.
- 5 mg vial at 2.5 mg twice weekly = ~1 week of supply
- Cost per 2.5 mg dose (from a $250 vial): ~$125/dose
- Wolverine Stack weekly cost (BPC-157 + TB-500 at standard doses): ~$300–400/week
Frequently Asked Questions
Is TB-500 the same as Thymosin Beta-4?
Practically, in clinical conversation, yes. Technically, TB-500 historically referred to a synthetic fragment of the active actin-binding region of Tβ4. Compounding pharmacies in 2026 may dispense either the fragment or full-length Tβ4 depending on the product. The dosing protocols are functionally interchangeable.
Why is TB-500 dosed only twice a week?
Tβ4 has a short plasma half-life (~2 hours) but a much longer functional half-life in tissue (likely days), because it binds to large intracellular actin pools. Once tissue is saturated, twice-weekly dosing maintains that saturation.
Do I need a loading dose?
Loading-then-maintenance is the classic TB-500 protocol pattern, used widely in both community and clinical contexts. A typical loading phase is 5 mg twice weekly for 2 weeks, then maintenance at 2.5 mg twice weekly. For minor injuries or maintenance use, many patients skip the loading phase and start directly at 2–2.5 mg twice weekly.
Is TB-500 banned in sport?
Yes. Thymosin Beta-4 is on the World Anti-Doping Agency (WADA) prohibited list. Athletes subject to drug testing should not use TB-500 outside of an explicit therapeutic-use exemption.
What’s the standard injection schedule?
Most protocols use Monday/Thursday or Tuesday/Friday, roughly 3–4 days apart. Site rotation between left and right abdomen, or abdomen and thigh, is standard.
How long until I notice a benefit?
Community reports for soft-tissue injury commonly describe perceptible benefit at 2–4 weeks, with peak effects at 4–6 weeks. Tendon and ligament protocols may extend longer. There is no validated clinical timeline because Phase 3 efficacy trials in tissue repair indications have not been completed.
Educational use only, not medical advice. Consult your prescribing physician.
- Demand a current third-party Certificate of Analysis (CoA) listing peptide identity (mass spec), purity ≥98%, and endotoxin testing.
- Verify the lyophilized vial weight matches what’s printed – under-filled vials are the most common form of dose-cheating in this market.
- Storage: Reconstituted TB-500 is stable refrigerated for ~28 days. Lyophilized stock years at -20°C.
- Typical research route: subcutaneous or IM.
- TB-500 is the synthetic acetylated fragment of thymosin beta-4. Full-length thymosin beta-4 is a different molecule with a different price point.
- “Research-use-only” labeling has legal weight – self-administration may violate state and federal law in your jurisdiction.
References
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PubMed.
- Crockford D, Turjman N, Allan C, Angel J. Thymosin beta-4: structure, function, and clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. PubMed.
- Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta-4 suppression of corneal NF-kappaB. Exp Eye Res. 2007;84(4):663-669. PubMed.
- Ruff D, Crockford D, Girardi G, Zhang Y. Single and multiple dose study of intravenous thymosin beta-4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. PubMed.
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. FDA.
- World Anti-Doping Agency. Prohibited List 2026, Section S2. WADA.
- National Library of Medicine. PubMed search: TB-500 thymosin beta-4 healing. PubMed.
Related tools: Compare TB-500 with similar peptides · See TB-500’s goal category






